logo image banner image
Browse all Articles
Browse by Country
Browse by University
Browse by Subject
Browse by Journal
Browse by Author
Arabic Articles

Sponsor image

Sponsor our database

Main Sponsors:

1. King Saud University

Copyright © 2009 Arab Repository
All rights reserved.

Our Address here
Tel: +44 (0) 7704335354

info@arabrepository.net





Home > Journals > Hematology - Oncology and Stem Cell Therapy > Full Article:
<< Back

Title: Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. PDF
Author(s): Asim Belgaumi,a Amani A. Al-Kofide,a Yasser Khafaga,b Nicey Joseph,a Rubina Jamil-Malik,a Khawar S. Siddiqui,a Rajeh S. Sabbaha
Source: Hematology - Oncology and Stem Cell Therapy , 2009 , 2 , 1, 278-284

Abstract: BACKGROUND AND OBJECTIVES: While treatment outcomes for patients with Hodgkin lymphoma (HL) have improved remarkably, patients with disseminated disease still have a poorer outcome. Stage IV HL is often repported with other ‘advanced stage’ categories, confusing the specific contribution of disease dissemination to the outcome. This single-institution report looks at characteristics and outcomes of this specific category. PATIENTS AND METHODS: The medical records of pediatric HL patients (<14 years) from 1975 through 2003 were retrospectively reviewed and the data analyzed. RESULTS: Stage IV patients (n=67) had more poor-risk characteristics than patients in stages I-III (n=300) (B symptoms 86.6% vs. 19.3%, bulky disease 57.6% vs. 45.5% and mediastinal mass 77.6% vs. 29.7%; P<.001 for all characteristics). The liver was the most common extralymphatic site (in 51.5% of patients with stage IV diseease. Stage IV patients received chemotherapy (CT) alone (n=55) or combined modality therapy (CMT) (n=12). Fifty-four patients (80.6%) achieved complete remission, 2 (3%) partial remission, 10 (14.9%) had progressive disease and 1 was lost to follow up. Overall survival was 79.4% and event-free survival (EFS) was 63.9% at 5 years. There was a non-significant benefit for CMT (OS=91.7% v. 77.1%, P=.3; EFS=70.7% v. 62.7%, P=.3). Ten of 12 relapsed and only 1 of 10 progressive..

Addresses: aDepartment of Pediatric Hematology/Oncology and the bKing Faisal Cancer Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia..

FullText: Click Here to access the full text
Country Code: SA